BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Greenwald ZR, Maheu-Giroux M, Szabo J, Robin JAB, Boissonnault M, Nguyen VK, Thomas R. Cohort profile: l'Actuel Pre-Exposure Prophylaxis (PrEP) Cohort study in Montreal, Canada. BMJ Open 2019;9:e028768. [PMID: 31248931 DOI: 10.1136/bmjopen-2018-028768] [Cited by in Crossref: 15] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Meyers K, Nguyen N, Zucker JE, Kutner BA, Carnevale C, Castor D, Sobieszczyk ME, Yin MT, Golub SA, Remien RH. The Long-Acting Cabotegravir Tail as an Implementation Challenge: Planning for Safe Discontinuation. AIDS Behav 2022. [PMID: 36056997 DOI: 10.1007/s10461-022-03816-0] [Reference Citation Analysis]
2 Dietrich JJ, Ahmed N, Webb EL, Tshabalala G, Hornschuh S, Mulaudzi M, Atujuna M, Stranix-Chibanda L, Nematadzira T, Ssemata AS, Muhumuza R, Seeley J, Bekker LG, Weiss HA, Martinson N, Fox J; CHAPS team. A multi-country cross-sectional study to assess predictors of daily versus on-demand oral pre-exposure prophylaxis in youth from South Africa, Uganda and Zimbabwe. J Int AIDS Soc 2022;25:e25975. [PMID: 36002910 DOI: 10.1002/jia2.25975] [Reference Citation Analysis]
3 Molina J, Ghosn J, Assoumou L, Delaugerre C, Algarte-genin M, Pialoux G, Katlama C, Slama L, Liegeon G, Beniguel L, Ohayon M, Mouhim H, Goldwirt L, Spire B, Loze B, Surgers L, Pavie J, Lourenco J, Ben-mechlia M, Le Mestre S, Rojas-castro D, Costagliola D. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study. The Lancet HIV 2022. [DOI: 10.1016/s2352-3018(22)00133-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Zhang J, Li C, Xu J, Hu Z, Rutstein SE, Tucker JD, Ong JJ, Jiang Y, Geng W, Wright ST, Cohen MS, Shang H, Tang W. Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis. The Lancet HIV 2022;9:e254-68. [DOI: 10.1016/s2352-3018(22)00030-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
5 Orser L, O'Byrne P, Holmes D. Perceptions, motivations, and beliefs about HIV risk and pre-exposure prophylaxis (PrEP) among participants in a nurse-led PrEP service (PrEP-RN). BMC Infect Dis 2022;22:196. [PMID: 35227202 DOI: 10.1186/s12879-022-07146-3] [Reference Citation Analysis]
6 Flores Anato JL, Panagiotoglou D, Greenwald ZR, Blanchette M, Trottier C, Vaziri M, Charest L, Szabo J, Thomas R, Maheu-Giroux M. Chemsex and incidence of sexually transmitted infections among Canadian pre-exposure prophylaxis (PrEP) users in the l'Actuel PrEP Cohort (2013-2020). Sex Transm Infect 2022:sextrans-2021-055215. [PMID: 35039437 DOI: 10.1136/sextrans-2021-055215] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Giguère K, Vaziri M, Olivier C, Charest L, Szabo J, Thomas R, Maheu-Giroux M. Characteristics of new HIV diagnoses over 1995-2019: A clinic-based study in Montréal, Canada. PLoS One 2021;16:e0258383. [PMID: 34618875 DOI: 10.1371/journal.pone.0258383] [Reference Citation Analysis]
8 Hovaguimian F, Martin E, Reinacher M, Rasi M, Schmidt AJ, Bernasconi E, El Amari EB, Braun DL, Calmy A, Darling K, Christinet V, Depmeier C, Hauser C, Läuchli S, Notter J, Stoeckle M, Surial B, Vernazza P, Bruggmann P, Tarr P, Haerry D, Bize R, Low N, Lehner A, Böni J, Kouyos RD, Fehr JS, Hampel B. Participation, retention and uptake in a multicentre pre-exposure prophylaxis cohort using online, smartphone-compatible data collection. HIV Med 2021. [PMID: 34605153 DOI: 10.1111/hiv.13175] [Reference Citation Analysis]
9 Razmjou S, Charest M, O’byrne P, Macpherson P. Pre-Exposure Prophylaxis Among Gay, Bisexual, and Other Men Who Have Sex With Men in Ottawa: A Real World View With Benefits Beyond HIV Risk Reduction. International Journal of Sexual Health. [DOI: 10.1080/19317611.2021.1946731] [Reference Citation Analysis]
10 Brenner BG, Ibanescu RI, Osman N, Cuadra-Foy E, Oliveira M, Chaillon A, Stephens D, Hardy I, Routy JP, Thomas R, Baril JG, Leblanc R, Tremblay C, Roger M, The Montreal Primary Hiv Infection Phi Cohort Study Group. The Role of Phylogenetics in Unravelling Patterns of HIV Transmission towards Epidemic Control: The Quebec Experience (2002-2020). Viruses 2021;13:1643. [PMID: 34452506 DOI: 10.3390/v13081643] [Reference Citation Analysis]
11 Jongen VW, Reyniers T, Ypma ZM, Schim van der Loeff MF, Davidovich U, Zimmermann HM, Coyer L, van den Elshout MA, de Vries HJ, Wouters K, Smekens T, Vuylsteke B, Prins M, Laga M, Hoornenborg E. Choosing event-driven and daily HIV pre-exposure prophylaxis - data from two European PrEP demonstration projects among men who have sex with men. J Int AIDS Soc 2021;24:e25768. [PMID: 34382345 DOI: 10.1002/jia2.25768] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
12 Grulich AE, Jin F, Bavinton BR, Yeung B, Hammoud MA, Amin J, Cabrera G, Clackett S, Ogilvie E, Vaccher S, Vickers T, McNulty A, Smith DJ, Dharan NJ, Selvey C, Power C, Price K, Zablotska I, Baker DA, Bloch M, Brown K, Carmody CJ, Carr A, Chanisheff D, Doong N, Finlayson R, Lewis DA, Lusk J, Martin S, Ooi C, Read P, Ryder N, Smith D, Tuck Meng Soo C, Templeton DJ, Vlahakis E, Guy R; Expanded PrEP Implementation in Communities New South Wales (EPIC-NSW) research group. Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study. Lancet HIV 2021;8:e486-94. [PMID: 34217426 DOI: 10.1016/S2352-3018(21)00074-6] [Reference Citation Analysis]
13 Flores Anato JL, Panagiotoglou D, Greenwald ZR, Trottier C, Vaziri M, Thomas R, Maheu-Giroux M. Chemsex practices and pre-exposure prophylaxis (PrEP) trajectories among individuals consulting for PrEP at a large sexual health clinic in Montréal, Canada (2013-2020). Drug Alcohol Depend 2021;226:108875. [PMID: 34218004 DOI: 10.1016/j.drugalcdep.2021.108875] [Reference Citation Analysis]
14 Pagkas-Bather J, Khosropour CM, Golden MR, Thibault C, Dombrowski JC. Population-Level Effectiveness of HIV Pre-exposure Prophylaxis Among MSM and Transgender Persons With Bacterial Sexually Transmitted Infections. J Acquir Immune Defic Syndr 2021;87:769-75. [PMID: 33538527 DOI: 10.1097/QAI.0000000000002646] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Cox J, Apelian H, Moodie EEM, Messier-Peet M, Hart TA, Grace D, Moore DM, Lachowsky NJ, Armstrong HL, Jollimore J, Skakoon-Sparling S, Rodrigues R, Tan DHS, Maheu-Giroux M, Noor SW, Lebouché B, Tremblay C, Olarewaju G, Lambert G; Engage Study Team. Use of HIV pre-exposure prophylaxis among urban Canadian gay, bisexual and other men who have sex with men: a cross-sectional analysis of the Engage cohort study. CMAJ Open 2021;9:E529-38. [PMID: 34021010 DOI: 10.9778/cmajo.20200198] [Reference Citation Analysis]
16 Ramos SR, Lardier DT Jr, Boyd DT, Gutierrez JI Jr, Carasso E, Houng D, Kershaw T. Profiles of HIV Risk, Sexual Power, and Decision-Making among Sexual Minority Men of Color Who Engage in Transactional Sex: A Latent Profile Analysis. Int J Environ Res Public Health 2021;18:4961. [PMID: 34066948 DOI: 10.3390/ijerph18094961] [Reference Citation Analysis]
17 Wu L, Schumacher C, Chandran A, Fields E, Price A, Greenbaum A, Jennings JM; IMPACT Partner Collaborative. Patterns of PrEP Retention Among HIV Pre-exposure Prophylaxis Users in Baltimore City, Maryland. J Acquir Immune Defic Syndr 2020;85:593-600. [PMID: 32947447 DOI: 10.1097/QAI.0000000000002506] [Reference Citation Analysis]
18 Lima VD, Zhu J, Card KG, Lachowsky NJ, Chowell-Puente G, Wu Z, Montaner JSG. Can the combination of TasP and PrEP eliminate HIV among MSM in British Columbia, Canada? Epidemics 2021;35:100461. [PMID: 33984688 DOI: 10.1016/j.epidem.2021.100461] [Reference Citation Analysis]
19 Xia Y, Greenwald ZR, Milwid RM, Trottier C, Boissonnault M, Gaul N, Charest L, Landry G, N Zahedi N, Szabo J, Thomas R, Maheu-Giroux M. Pre-exposure Prophylaxis Uptake Among Men Who Have Sex With Men Who Used nPEP: A Longitudinal Analysis of Attendees at a Large Sexual Health Clinic in Montréal (Canada). J Acquir Immune Defic Syndr 2020;85:408-15. [PMID: 33136737 DOI: 10.1097/QAI.0000000000002472] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
20 Doyle CM, Maheu-Giroux M, Lambert G, Mishra S, Apelian H, Messier-Peet M, Otis J, Grace D, Hart TA, Moore DM, Lachowsky NJ, Cox J; Engage Study Team. Combination HIV Prevention Strategies Among Montreal Gay, Bisexual, and Other Men Who Have Sex with Men in the PrEP Era: A Latent Class Analysis. AIDS Behav 2021;25:269-83. [PMID: 32648063 DOI: 10.1007/s10461-020-02965-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
21 Spinelli MA, Laborde N, Kinley P, Whitacre R, Scott HM, Walker N, Liu AY, Gandhi M, Buchbinder SP. Missed opportunities to prevent HIV infections among pre-exposure prophylaxis users: a population-based mixed methods study, San Francisco, United States. J Int AIDS Soc 2020;23:e25472. [PMID: 32294338 DOI: 10.1002/jia2.25472] [Cited by in Crossref: 9] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
22 Rutstein SE, Smith DK, Dalal S, Baggaley RC, Cohen MS. Initiation, discontinuation, and restarting HIV pre-exposure prophylaxis: ongoing implementation strategies. Lancet HIV 2020;7:e721-30. [PMID: 32861269 DOI: 10.1016/S2352-3018(20)30203-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]